Avantel Q1FY27 Net Profit Rises 65% YoY to ₹761.77 Lakh; EBITDA Margin Expands
Avantel reported Q1FY27 standalone net profit of ₹761.77 lakh, up from ₹46M rupees YoY, with revenue from operations at ₹7012.34 lakh versus ₹518M rupees in the prior year period. EBITDA improved to ₹191M rupees from ₹114M rupees YoY, with EBITDA margin expanding to 27.30% from 21.89%. The Board also approved key managerial appointments and remuneration revisions at its July 11, 2026 meeting.

*this image is generated using AI for illustrative purposes only.
Avantel Limited reported a standalone net profit of ₹761.77 lakh for the first quarter ended June 30, 2026, reflecting a strong year-on-year (YoY) growth compared to ₹46M rupees in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹7012.34 lakh (₹701M rupees), up from ₹518M rupees in the corresponding quarter of the prior year. The company's total income for Q1FY27 was ₹7023.89 lakh, while revenue from operations in the preceding quarter ended March 31, 2026, was ₹6314.66 lakh.
The Board of Directors, at its meeting held on July 11, 2026, approved the unaudited standalone and consolidated financial results for the period. The results were reviewed by the Statutory Auditors and the Audit Committee. The company operates in a single segment, focusing on communications and signal processing products, and noted that its principal customer is an organization controlled by the Government of India, which influenced its decision regarding loss allowance provisions.
Financial Performance
Avantel's standalone financial results for the quarter ended June 30, 2026, reflect broad-based improvement across key metrics on both a sequential and year-on-year basis. EBITDA for the quarter came in at ₹191M rupees, compared to ₹114M rupees in Q1 of the previous year, while the EBITDA margin expanded to 27.30% from 21.89% YoY. Total expenses for the quarter were ₹5931.69 lakh, and profit before tax stood at ₹1092.20 lakh. The basic and diluted earnings per equity share (face value ₹2) stood at ₹0.29 for the quarter.
The following table summarises the standalone financial performance across reporting periods (all figures in ₹ lakh unless stated):
| Particulars: | Q1FY27 (30/06/2026) Unaudited | Q4FY26 (31/03/2026) Audited | FY26 (31/03/2026) Audited |
|---|---|---|---|
| Revenue from Operations: | ₹7012.34 | ₹6314.66 | ₹22135.23 |
| Total Income: | ₹7023.89 | ₹6423.54 | ₹22380.90 |
| Total Expenses: | ₹5931.69 | ₹5461.29 | ₹19163.69 |
| Net Profit for the Period: | ₹761.77 | ₹705.23 | ₹2249.97 |
| Earnings per Share (Basic): | ₹0.29 | ₹0.29 | ₹0.92 |
The YoY performance highlights a significant improvement across key operating metrics:
| Metric: | Q1FY27 | Q1FY26 | Change (YoY) |
|---|---|---|---|
| Net Profit: | ₹76M | ₹46M | Higher YoY |
| Revenue from Operations: | ₹701M | ₹518M | Higher YoY |
| EBITDA: | ₹191M | ₹114M | Higher YoY |
| EBITDA Margin: | 27.30% | 21.89% | Expanded YoY |
On a consolidated basis, which includes subsidiary iMeds Global Private Limited, the company reported a net profit of ₹539.46 lakh for Q1FY27, compared to ₹477.47 lakh in the previous quarter. Total consolidated revenue from operations was ₹7042.16 lakh. The subsidiary reported a net loss of ₹222.31 lakh for the quarter, which the management stated is not material to the Group.
Board Decisions and Appointments
The Board approved the revision of remuneration for Mr. Abburi Siddhartha Sagar, Executive Director (Strategy & Business Development), from ₹48.00 Lakhs per annum to ₹55 Lakhs per annum, effective July 11, 2026. Additionally, the Board approved the re-appointment of Mr. Abburi Siddhartha Sagar for a further term of five years commencing March 8, 2027, subject to shareholder approval via postal ballot.
Mr. Peddi Bala Bhaskar Rao was appointed as an Additional Director designated as Director (Operations) for a term of three years effective July 11, 2026, subject to shareholder approval. The Board also approved the re-appointment of Mr. Vyasabhattu Ramchander as an Independent Director for a second consecutive term of five years from May 6, 2027, subject to approval by a special resolution through postal ballot. The Board further reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee with immediate effect.
Historical Stock Returns for Avantel
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.21% | +0.01% | +7.27% | +15.20% | +11.09% | -7.22% |
How will the company's dependence on a single government-controlled customer impact its revenue stability and order book visibility in the coming quarters?
What strategic measures are being implemented to turn around the performance of the loss-making subsidiary, iMeds Global Private Limited?
Can the expanded EBITDA margin of 27.30% be sustained throughout FY27 given the sequential increase in total expenses?































